SEKISUI CHEMICAL: Filing of Lawsuit Seeking Injunction and Damages for Patent Infringement in Relation to PVB Interlayer in Germany and Korea
The High Performance Plastics Company (President: Ikusuke Shimizu) of SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Keita Kato; hereinafter “SEKISUI CHEMICAL”) has filed lawsuits for infringement of its European patent 2 017 237 (“EP ’237”), European patent 3 208 247 (“EP ’247”), European patent 3 357 888 (“EP ’888”) and European patent 3 392 222 (“EP ’222”) against Kuraray Europe GmbH (hereinafter “Kuraray Europe”), a subsidiary of Kuraray Co., Ltd., as the defendant before the District Courts Munich I (docket No. 7 O 12401/24, docket No. 7 O 12476/24 and docket No. 7 O 12477/24) and Mannheim (docket No. 2 O 92/24) in Germany.
The lawsuits based on EP ’237 and EP ’247 relating to sound control properties of a PVB Interlayer and based on EP ’888 relating to shrinkage properties of a PVB Interlayer owned by SEKISUI CHEMICAL and asserted before the District Court Munich I, seek, inter alia, injunctions against the manufacture and offering for sale etc. of “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” sound insulation wedge products manufactured and offered for sale by Kuraray Europe in Germany, as well as, inter alia, declaratory judgments on liability for damages.
The lawsuit based on EP ’222 relating to glossiness for a PVB Interlayer, owned by SEKISUI CHEMICAL and asserted before the District Court Mannheim, seeks, inter alia, an injunction against the manufacture and offering for sale etc. of “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” sound insulation wedge products manufactured and offered for sale by Kuraray Europe in Germany, as well as, inter alia, a declaratory judgement on liability for damages.
SEKISUI CHEMICAL has filed a patent infringement lawsuit against Kuraray Korea Ltd. (hereinafter “Kuraray Korea”), a subsidiary of Kuraray Co., Ltd., as the defendant in the Seoul Central District Court of Korea.
Based on the Korean patent for PVB Interlayer owned by SEKISUI CHEMICAL, the lawsuit seeks an injunction against the manufacture and sale, etc. in Korea of ‘Trosifol’ The Wedge Acoustic and ‘Trosifol’ The Wedge Acoustic Shadeband, sound insulation wedge products manufactured and sold by Kuraray Korea, and damages.
SEKISUI CHEMICAL regards its intellectual property rights as an important management resource. It will take strict action in cases where it determines that SEKISUI CHEMICAL Group’s intellectual property rights have been infringed.
About SEKISUI CHEMICAL Group
Headquartered in Japan, SEKISUI CHEMICAL CO., LTD. (TSE: 4204) and its subsidiaries make up the SEKISUI CHEMICAL Group. 26,000 employees in over 156 companies throughout 20 countries and regions aim to contribute to improving the lives of the people of the world and the earth’s environment. Thanks to a history of innovation, dedication and a pioneering spirit, SEKISUI CHEMICAL now holds leading positions in its three diverse business divisions as well as top global market share in interlayer film, foam products, conductive particles and more.
Disclaimer
This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101799415/en/
Contacts
SEKISUI CHEMICAL CO., LTD.
Corporate Communication Department
Email: kouhou@sekisui.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom